Subsidiary of Zhejiang East-Asia Pharmaceutical (605177.SH) Fumaric acid levofenol raw material pharmaceutical obtained South Korea raw material pharmaceutical registration certificate.

date
15:53 08/05/2026
avatar
GMT Eight
Dongya Pharmaceutical (605177.SH) announced that its wholly-owned subsidiary Jiangxi Shanyuan Pharmaceutical Co., Ltd. has recently received the Active Pharmaceutical Ingredient Registration Certificate from the South Korean Ministry of Food and Drug Safety (MFDS).
Zhejiang East-Asia Pharmaceutical (605177.SH) announced that its wholly-owned subsidiary, Jiangxi Shanyuan Pharmaceutical Co., Ltd., has received the raw material drug registration certificate from the South Korean Ministry of Food and Drug Safety (MFDS). Famotidine Fuanolat is a potassium ion competitive acid blocker (P-CAB) that can inhibit the production of stomach acid and prevent damage to the upper gastrointestinal mucosa. It is mainly used to treat gastroesophageal reflux disease and is used in combination with appropriate antibiotics to eradicate Helicobacter pylori. Data shows that the sales of Famotidine Fuanolat-related products in China in 2025 are estimated to be around 722 million RMB, and the global sales are estimated to be around 8.25 billion RMB in 2025.